GSK3β‑mediated NFATc3 phosphorylation as an age‑specific brake on the calcineurin‑NFAT‑miR‑23a axis that unmasks compensatory atrophy pathways

Hypothesis

In aged skeletal muscle, chronic GSK3β‑dependent phosphorylation of NFATc3 promotes its cytoplasmic retention and proteasomal turnover, uncoupling calcineurin activity from NFAT‑driven miR‑23a expression. This creates a permissive state for atrophy‑gene transcription despite intact or even elevated calcineurin signaling, and explains why MuRF1 deletion fails to protect very old mice: low NFATc3 permits compensatory AP‑1‑dependent induction of alternative E3 ligases (atrogin‑1, Murf2) that sustain protein breakdown.

Mechanistic Rationale

1. GSK3β as an age‑specific NFATc3 kinase – Aging elevates oxidative stress and inflammatory cytokines (e.g., TNF‑α, IL‑6) that activate GSK3β via AKT inhibition 4. GSK3β phosphorylates NFATc3 on conserved serine residues downstream of its calcineurin‑dependent dephosphorylation sites, creating a phosphodegron recognized by β‑TrCP.

2. Failed miR‑23a repression – Phosphorylated NFATc3 cannot enter the nucleus, so the miR‑23a promoter remains inactive. Consequently, MuRF1 and atrogin‑1 mRNAs escape microRNA‑mediated repression, even if calcineurin activity is transiently elevated by calcium leaks 1.

3. AP‑1 synergy – Low nuclear NFATc3 relieves its antagonistic interaction with c‑Jun/JUNB, allowing AP‑1 to drive transcription of atrogenes. In young muscle, NFATc3 competes for AP‑1 binding sites, limiting this drive; in aged muscle, the competition is lost.

4. Compensatory E3 ligase induction – When MuRF1 is genetically removed, AP‑1‑dependent up‑regulation of atrogin‑1 and Murf2 maintains ubiquitin‑proteasome activity, accounting for the loss of protection in 24‑month‑old mice 2.

Testable Predictions

• Prediction 1: In tibialis anterior muscles from 24‑month‑old mice subjected to dexamethasone, NFATc3 will show increased serine phosphorylation (p‑Ser) and reduced nuclear fraction compared with 3‑month‑old controls, while total NFATc3 protein declines due to enhanced ubiquitination.
• Prediction 2: Pharmacological inhibition of GSK3β (e.g., CHIR99021) or muscle‑specific knockdown of RCAN1 will restore NFATc3 nuclear localization, increase miR‑23a levels, and attenuate MuRF1/atrogin‑1 induction in old mice during atrophy.
• Prediction 3: Combining MuRF1 knockout with GSK3β inhibition will produce additive preservation of muscle force and fiber cross‑sectional area in aged mice, whereas GSK3β inhibition alone will rescue the MuRF1 knockout phenotype.
• Prediction 4: Chromatin immunoprecipitation will reveal increased c‑Jun binding to the atrogin‑1 and Murf2 promoters in aged atrophic muscle, which diminishes when GSK3β is inhibited.

Experimental Approach

• Use western blot and phospho‑specific antibodies to quantify NFATc3 p‑Ser levels in cytosolic and nuclear fractions.
• Measure miR‑23a by qRT‑PCR and downstream E3 ligase mRNA/protein.
• Administer GSK3β inhibitor systemically or via AAV‑mediated shRNA targeting GSK3β in tibialis anterior.
• Assess muscle grip strength, treadmill endurance, and histomorphometry.
• Perform ChIP‑qPCR for c‑Jun and NFATc3 at atrogene promoters.

If these predictions hold, the data would position GSK3β‑mediated NFATc3 inactivation as a central node linking age‑related calcium dysregulation, inflammatory signaling, and the failure of single‑gene atrophy interventions, offering a combinatorial therapeutic strategy.